The invention provides an anti-tumor necrosis factor human-derived monoclonal antibody and application of the human-derived monoclonal antibody. Compared with the traditional mouse chimeric antibody, the anti-tumor necrosis factor human-derived monoclonal antibody has the advantages that the antigen identifying capability of the antibody is kept, and the immunogenicity of mouse-derived antibody is greatly reduced, so that the clinical application security of the antibody is improved.